Over 4,375 churches, synagogues, and organizations in 13 countries worldwide to plant more than 5.2 million flags & stand in prayer, remembrance and solidarity with Israel and the Jewish people throughout October

CHICAGO, Oct. 2, 2026 /PRNewswire-HISPANIC PR WIRE/ — The International Fellowship of Christians and Jews (The Fellowship) announced today that participation in its annual October 7 remembrance movement, Flags of Fellowship (FOF), has more than doubled since 2025, with more than 4,375 churches, synagogues, universities, and organizations worldwide set to mark the third anniversary of the attacks. In total, more than 5.2 million flags will be planted globally as part of the third annual campaign.

From October 2-11 and throughout the month of October, participating organizations will display fields of 1,200 mini Israeli flags and hold special FOF events, worship services, and community gatherings to visually and vocally demonstrate their support for Israel during this time of unprecedented anti-Semitism worldwide.

10 leading evangelical churches across Tennessee, Illinois, New Jersey, California, Texas, Oklahoma, Florida, and Virginia will serve as flagship churches for this year’s FOF events, with some locations hosting special guest speakers including local dignitaries and October 7 survivors at their events.

Flags of Fellowship has also expanded significantly beyond the U.S. and Canada this year, with more than 1,775 international churches and organizations participating from 11 countries, including Australia, England, Kenya, South Africa, India, the UAE, and more.

“While much attention has been given since October 7 to stories of division and hatred, a different story—one of friendship between Christians and Jews—is being written in churches and homes across America and the world through Flags of Fellowship,” said Yael Eckstein, President and Global CEO of The Fellowship.

The movement began in 2024 with more than 220 participating organizations, and grew to more than 1,300 participants last year.

“When a church plants an Israeli flag, it is not making a political statement, it is making a spiritual one—a declaration of friendship, remembrance, and faithfulness to those who are hurting,” Eckstein added. “That is what I hope people see when they look at Flags of Fellowship—not simply flags, but friendship. Not simply remembrance, but solidarity. Because we know that together, we can transform mourning into meaning, and loss into lasting light.”

A key driver of the campaign’s international growth is its new hub model, through which leading churches serve as regional distribution centers and equip churches in their networks with flags and campaign materials. Hubs in Colombia, Mexico, and Guatemala alone represent approximately 1,050 participating churches.

In Colombia, approximately 1,000 churches across eight major cities are expected to display more than 1.2 million Israeli flags in October as part of Flags of Fellowship.

“Colombia is a nation of faith, and our churches have a deep desire to support Israel and the Jewish people,” said César Fernández, a Fellowship Ambassador Pastor. “We believe that the Colombian Church has a unique voice and a significant role to play in strengthening this bridge of friendship between Christians and Jews, and we’re proud and excited to see Colombia take its place in this global movement of Flags of Fellowship.”

Since October 7, 2023, The Fellowship has committed $432 million in aid to Israel to meet emergency needs while continuing its core humanitarian programs, including emergency food and water, equipment for first responders and security personnel, support for olim making aliyah, and aid to vulnerable populations affected by the war and ongoing conflict.

For more information, or to learn how to participate in Flags of Fellowship in 2027, visit www.ifcj.org/FOF.

About the International Fellowship of Christians and Jews
For more than 40 years, the International Fellowship of Christians and Jews (The Fellowship) has been the leading nonprofit building bridges between Christians and Jews, blessing Israel and the Jewish people around the world with humanitarian care and lifesaving aid. In 2025, The Fellowship helped more than 2 million people living in poverty, helped thousands make aliyah back to their homeland, Israel, and helped strengthen Israel’s security infrastructure. To learn more about The Fellowship’s work, visit www.ifcj.org.

About Yael Eckstein
Yael Eckstein is President and Global CEO of The Fellowship, one of the world’s largest religious charitable organizations, and is a respected Jewish leader, speaker, bestselling author, and an award-winning podcast host and humanitarian. A 2025 ‘Pillars of Jerusalem’ award recipient for her exceptional contributions to Israel’s public diplomacy, and The Jerusalem Post’s 2023 Humanitarian of the Year, Yael is a Chicago-area native based in Israel with her husband and their four children.

Media Contact: press@ifcj.org

SOURCE International Fellowship of Christians and Jews

VANCOUVER, BC, Oct. 2, 2026 /CNW/ — Light AI Inc. (“Light AI” or the “Company”) (Cboe CA: ALGO; (FSE: 0HC) (OTCQB: OHCFF) today announced that it will keep its QuickScan™ Strep A software-as-a-medical-device (“SaMD”) in controlled product development and continue its hold on related clinical activities.

Management made this decision following a preliminary product, quality and verification and validation (“V&V”) assessment that identified gaps in the objective evidence currently available to substantiate performance of the complete QuickScan™ Strep A system across its intended-use population and use environment. The assessment includes machine-learning development and validation evidence, datasets, image acquisition and processing, software and system V&V, design controls, usability, cybersecurity and supporting quality-system documentation.

As a result, the Company will not resume external clinical validation or advance toward a U.S. Food and Drug Administration (“FDA”) submission until the product configuration and supporting objective evidence establish readiness for clinical use.

Action Plan

The Company will undertake a structured technical and quality action plan that will include:

continuing the hold on its New Zealand feasibility activities and planned U.S. clinical study;conducting an independent robustness assessment of the existing machine-learning model and supporting datasets;determining whether the existing model can be remediated and/or retrained or whether redevelopment is required;continuing to evaluate controlled imaging alternatives to the current smartphone-based image-acquisition approach; andcompleting the required design-control, quality-system and system-level V&V activities.

The preliminary assessment has not reached a conclusion on the underlying technology’s ability to achieve its target performance or on whether the existing machine-learning model can be retrained rather than redeveloped; those questions will be addressed through the independent robustness assessment described above. Management has concluded that the Company does not currently have sufficient objective evidence to rely upon the existing product configuration and validation package for further clinical deployment or advancement toward an FDA submission without additional development, remediation and V&V.

Expected Implications

The timing of the Company’s previously contemplated U.S. clinical and FDA regulatory activities is being reassessed. The Company will not provide a revised timetable until the relevant development, remediation and V&V work has progressed sufficiently to support a reliable assessment of next steps.

“Patient safety, product performance and objective scientific evidence are the foundation of our development program,” said John R. Luna, Chief Executive Officer and Director of Light AI. “Our review identified gaps in the evidence supporting the performance of the complete QuickScan™ system, and we are addressing them directly. Before we resume clinical studies, we intend to complete the development, design-control and validation work necessary to establish that the product performs as intended across its intended-use population and use environment. This is a setback in timing, but doing this work now is the right path to building a product that clinicians and patients can rely on.”

The Company’s Health Canada Class II medical device license, as disclosed in the Company’s news release dated August 12, 2026, remains in effect. The Company is assessing the findings of its review and any resulting regulatory obligations in consultation with its regulatory advisors.

The Company expects to provide its next update when it has reached material milestones or decisions regarding the machine-learning assessment, imaging architecture, remediation program, clinical activities or regulatory strategy.

About Light AI Inc. (CBOE CA: ALGO / FSE: 0HC / OTCQB: OHCFF)

Light AI Inc. is a healthcare technology company focused on developing artificial intelligence-powered SaMD solutions designed to support rapid, accessible clinical assessment at the point of care.

The Company’s core technology, Light AI QuickScan™, is a device-agnostic software platform that applies proprietary artificial intelligence and machine learning algorithms to medical images to provide healthcare professionals with actionable clinical information within seconds. The QuickScan™ platform is designed to operate across compatible imaging and computing hardware, providing flexibility for integration into a range of healthcare devices, clinical workflows and care settings without dependence on a single proprietary hardware platform.

ON BEHALF OF THE COMPANY

“John R. Luna”
Chief Executive Officer

For more information, please contact the Company at investors@light.ai or visit https://light.ai/.

Website: https://light.ai/
LinkedIn: LinkedIn/company/Light AI
X (Formerly Twitter): @lightaihealth

Forward-Looking Information:

This news release contains “forward-looking statements” and “forward-looking information” within the meaning of applicable Canadian securities legislation. All statements contained herein that are not clearly historical in nature may constitute forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “anticipate,” “believe,” “expect,” “estimate,” “intend,” “plan,” “project,” “target,” “potential,” “will,” “may,” “could,” “should,” “would,” and similar expressions.  These forward looking statements include the Company’s expectations regarding its anticipated technical and quality remediation program, including the assessment and the evaluation of the underlying technology and the existing machine-learning model, the timing and resumption of external clinical validation activities and advancement toward an FDA submission, the Company’s regulatory strategy and potential regulatory obligations, and the Company’s business strategy, development plans, and market opportunities.  Forward looking statements are subject to certain risks and uncertainties inherent in the Company’s business that could cause actual results to vary, including such risks with the Company’s ability to successfully execute its business plans, the Company’s ability to raise additional capital, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, the QuickScan™ platform does not perform as anticipated in clinical or actual patient settings, risks associated with the development, validation, and ongoing performance of artificial intelligence and machine learning algorithms, including algorithmic bias, data quality issues, and cybersecurity vulnerabilities, protection offered by the Company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company’s products will not be as large as expected, and other risks detailed from time to time in the Company’s documents filed under its SEDAR+ profile at www.sedarplus.ca. Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking statement speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.  The Company does not undertake any obligation to update any forward-looking information to reflect information, events, results, circumstances or otherwise after the date hereof or to reflect the occurrence of unanticipated events, except as required by law including securities laws.

SOURCE Light AI Inc.

National class action law firm offers free, confidential case evaluations to patients whose personal and protected health information may have been exposed in the Atlantic Digestive Specialists data breach.

NEWTOWN, Pa., Oct. 2, 2026 /PRNewswire/ — Edelson Lechtzin LLP, a national class action law firm, is investigating data privacy claims arising from a reported data breach at Atlantic Digestive Specialists. Anyone who has received a data breach notice from Atlantic Digestive Specialists, or who believes their personal information may have been exposed, can request a free case evaluation.

Atlantic Digestive Specialists data breach — at a glance

Company: Atlantic Digestive Specialists is a private gastroenterology practice in New Hampshire, with clinics in Somersworth, Portsmouth, and Hampton.Reported: Atlantic Digestive began notifying affected individuals on September 30, 2026, and reported the incident to state regulators.How it happened: Atlantic Digestive was alerted to suspicious activity on its network in March 2026 and investigated with cybersecurity experts.When: The unauthorized access occurred between March 16 and March 17, 2026, and a review concluding in August 2026 confirmed personal and protected health information was involved.Who may be affected: Patients whose personal or protected health information was maintained by Atlantic Digestive Specialists and who received a notification letter.Status: At least 51 Rhode Island residents were notified; the total number affected and the attacker’s identity have not been publicly confirmed.Cost to you: Nothing. Click here for a free evaluation.

What Happened

Atlantic Digestive was alerted to suspicious activity on its network in March 2026 and investigated with cybersecurity experts. It determined that information may have been viewed or acquired without authorization between March 16 and March 17, 2026. A review concluding in August 2026 confirmed that personal and protected health information was in the affected data, and Atlantic Digestive began notifying individuals on September 30, 2026. The total affected has not been publicly confirmed, though the notice reports at least 51 Rhode Island residents were notified.

What Personal Information May Be at Risk

Based on Atlantic Digestive’s review, the information involved varied by individual and spans a broad range of identifiers and protected health information. It may include names, Social Security numbers, driver’s license or state ID numbers, dates of birth, financial account and payment card information, passport, taxpayer, and alien registration numbers, and health data such as clinical information, diagnoses, medical histories and record numbers, treatment and prescription information, Medicaid/Medicare numbers, provider names, health insurance policy numbers, and usernames and passwords.

Your Legal Options

Edelson Lechtzin LLP is investigating a potential class action on behalf of patients whose sensitive personal and health information may have been compromised. A successful case could recover compensation for losses such as lost time, out-of-pocket costs, and loss of privacy, and could push Atlantic Digestive Specialists to strengthen how it protects personal information. Anyone who received a breach notification may face an increased risk of identity theft and fraud and is encouraged to come forward. The firm will evaluate your rights and potential claims at no cost.

Recommended Steps to Protect Yourself

Preserve your notification letter and monitor your account statements and credit reports for suspicious activity, reporting anything unfamiliar to your financial institution.

Request your free annual credit reports at annualcreditreport.com, and consider placing a fraud alert or security freeze with Equifax, Experian, and TransUnion.

Because medical and insurance information may be involved, review explanation-of-benefits statements for services you did not receive, and watch for medical identity theft.

Call Atlantic Digestive’s toll-free help line at 1-866-200-0962 (Monday–Friday, 9:00 a.m.–9:00 p.m. ET) with questions, and review the FTC’s identity-theft resources at ftc.gov/idtheft.

Contact Us for a Free Case Evaluation

Speak confidentially with a data privacy attorney today: Marc Edelson, Esq., Edelson Lechtzin LLP, 411 S. State Street, Suite N-300, Newtown, PA 18940; Phone: 844-696-7492; Email: medelson@edelson-law.com; Web: www.edelson-law.com.

About Edelson Lechtzin LLP

Edelson Lechtzin LLP is a national class action law firm with offices in Pennsylvania and California. In addition to data breach litigation, the firm handles class and collective actions involving securities and investment fraud, federal antitrust violations, ERISA employee benefit plans, wage theft, and consumer fraud.

Legal Notice: This press release may be considered Attorney Advertising in some jurisdictions. Prior results do not guarantee a similar outcome. The data breach described above is based on Atlantic Digestive Specialists’ notice of the incident; certain details, including the total number of individuals affected, remain unconfirmed.

View original content to download multimedia:https://www.prnewswire.com/news-releases/atlantic-digestive-specialists-data-breach-investigation-edelson-lechtzin-llp-probes-class-action-claims-after-customer-data-is-exposed-302897582.html

SOURCE Edelson Lechtzin LLP